An ascending multiple-dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAM-315 administered orally to healthy young adult and elderly subjects
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2010
At a glance
- Drugs SAM 315 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 24 Jan 2008 The expected completion date for this trial is now 1 Apr 2008.
- 24 Jul 2007 Status changed from initiated to recruiting.
- 21 Jul 2007 New trial record.